Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3528-3528
◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3529-3529
◽
Keyword(s):
Keyword(s):
Keyword(s):
2005 ◽
Vol 23
(16_suppl)
◽
pp. 3525-3525
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS3625-TPS3625
◽
Keyword(s):